Seoulin Bioscience Co.,Ltd. Stock: price and insider trades · South Korea
서린바이오
No insider purchase over the last 90 days. The latest, by 황을문, was filed 02 Apr 2026.
Seoulin Bioscience Co.,Ltd.: what insiders have been doing
Every trade that managers of Seoulin Bioscience Co.,Ltd. disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. 5 insiders have disclosed 6 filings since 1 November 2025.
Every open-market trade in the period is a purchase: 5 purchases, from 4 insiders, and not a single sale. The totals exclude 5 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 2 chief executives and 1 board member.
The latest purchase dates back some time: it was published 220 days ago, on 2 April 2026. Typically, a trade is published a median of 7 days after it takes place. That lag is the time during which only the insider knows about the trade.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 6 filings, this issuer sits below that mark. Over the whole record (from 2021), the tally stands at 19 purchases and 1 sale.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -41.6%Entry ₩6,100 · Close 30 Oct 2026 ₩3,565
- -41.6%Entry ₩6,100 · Close 30 Oct 2026 ₩3,565
- -41.6%Entry ₩6,100 · Close 30 Oct 2026 ₩3,565
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 57,737 sharesShareKRXDART:20260402001073Canonical exit: 24 Jun 2026 (T+90)
- 203 sharesShareKRXDART:20260402001083Canonical exit: 24 Jun 2026 (T+90)
- 49 sharesShareKRXDART:20260402001097Canonical exit: 24 Jun 2026 (T+90)
- ●Executives0DART
- 2,300 sharesShareKRXDART:20260204000114Canonical exit: 5 May 2026 (T+90)
- 532,236 sharesKRXDART:20260113000056Canonical exit: 19 Mar 2026 (T+90)
- 90,814 sharesKRXDART:20250409001791
- ●Executives0DART
- 20,491 sharesKRXDART:20250109000116Canonical exit: 20 Mar 2025 (T+90)
- ShareKRXDART:20230328000302Canonical exit: 26 Jun 2023 (T+90)
- ShareKRXDART:20230328000299Canonical exit: 26 Jun 2023 (T+90)
- ShareKRXDART:20230328000301Canonical exit: 26 Jun 2023 (T+90)
- 199 sharesShareKRXDART:20220323000420Canonical exit: 16 Jun 2022 (T+90)
- 2,000 sharesShareKRXDART:20220323000423Canonical exit: 16 Jun 2022 (T+90)
- 56,670 sharesShareKRXDART:20220323000411Canonical exit: 16 Jun 2022 (T+90)
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- 20,491 sharesKRXDART:20210521000372Canonical exit: 19 Aug 2021 (T+90)
- ShareKRXDART:20210521000368Canonical exit: 19 Aug 2021 (T+90)
- 20,491 sharesKRXDART:20210412002362Canonical exit: 11 Jul 2021 (T+90)
- ShareKRXDART:20210402001133Canonical exit: 1 Jul 2021 (T+90)
- ShareKRXDART:20210402001150Canonical exit: 1 Jul 2021 (T+90)
- ●Executives0DART
- 20,491 sharesKRXDART:20210304000249Canonical exit: 2 Jun 2021 (T+90)
25 of 26 declarations
About Seoulin Bioscience Co.,Ltd.
서린바이오 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the development of biopharmaceutical solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
